Next 10 |
home / stock / pstv / pstv articles
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a clinical-stage pharmaceuti...
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Cent...
AUSTIN, Texas, May 17, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company...
Company acquired assets for the synergistic leptomeningeal metastases (LM) diagnostic platform, "CNSide™" and discussed potential partnerin...
AUSTIN, Texas, May 06, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company...
Plus Therapeutics Inc (NASDAQ:PSTV) has been selected for $3 million in funding recommendation by the Department of Defense (DoD) office of th...
Plus now has $23 million in active awards support for the Company's targeted radiotherapeutic pipeline Funding for pediatric brain cancer tre...
AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical compa...
Plus Receives $3.3M in grant revenue in Q4 2023 Forecasts additional $6.9M of grant revenue for 2024 Enters into debt restructuring deal with Per...
News, Short Squeeze, Breakout and More Instantly...
PLUS THERAPEUTICS Inc. Company Name:
PSTV Stock Symbol:
NYSE Market:
PLUS THERAPEUTICS Inc. Website:
AUSTIN, Texas, July 02, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV ) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS...
Greg Fuller, M.D., Ph.D., former Professor of Pathology (Neuro-Pathology) & Neuro-Radiology at The University of Texas MD Anderson Cancer Center joins Plus as Vice President of Medical Affairs and Medical Director Plus receives notice of an additional $3.3 million CPRIT advance paym...
Announced private placement of up to $19.25M with healthcare funds and insiders Received $3M award recommendation from the Department of Defense to support Plus’ clinical brain cancer program Acquired synergistic leptomeningeal metastases diagnostic portfolio and announce...